Breakthroughs in SARS-CoV-2-monoclonal antibodies development
Muhammed, Y., Pius, M., Sani, B., Timothy, B., Usman, J., Garba, M. (2021). Breakthroughs in SARS-CoV-2-monoclonal antibodies development. EKB Journal Management System, 5(1), 1063-1076. doi: 10.21608/nrmj.2021.149375
Yusuf Muhammed; Mkpouto Pius; Bashiru Sani; Bulus Timothy; Jafar Usman; Musa Garba. "Breakthroughs in SARS-CoV-2-monoclonal antibodies development". EKB Journal Management System, 5, 1, 2021, 1063-1076. doi: 10.21608/nrmj.2021.149375
Muhammed, Y., Pius, M., Sani, B., Timothy, B., Usman, J., Garba, M. (2021). 'Breakthroughs in SARS-CoV-2-monoclonal antibodies development', EKB Journal Management System, 5(1), pp. 1063-1076. doi: 10.21608/nrmj.2021.149375
Muhammed, Y., Pius, M., Sani, B., Timothy, B., Usman, J., Garba, M. Breakthroughs in SARS-CoV-2-monoclonal antibodies development. EKB Journal Management System, 2021; 5(1): 1063-1076. doi: 10.21608/nrmj.2021.149375

Breakthroughs in SARS-CoV-2-monoclonal antibodies development

Novel Research in Microbiology Journal
Volume 5, Issue 1, January and February 2021, Page 1063-1076  XML PDF (683.85 K)
Document Type: Review Article
DOI: 10.21608/nrmj.2021.149375
View on SCiNiTO View on SCiNiTO
Authors
Yusuf Muhammed email 1; Mkpouto Pius2; Bashiru Saniorcid 3; Bulus Timothy4; Jafar Usman1; Musa Garba5
1Department of Biochemistry, Federal University Gusau, Nigeria
2Department of Medical Genetics, University of Cambridge, United Kingdom
3Department of Microbiology, Federal University Lafia, Nigeria
4Department of Biochemistry, Kaduna State University, Nigeria
5Faculty of Pharmaceutical Sciences Kaduna State University, Nigeria
Abstract
       In December 2019, cases of unknown pneumonia-like disease connected to food markets were reported in China. The causative agent was identified as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and the disease which spread all over the world, was named COVID-19. This pandemic has negatively affected quality of life and economy worldwide, thus motivating thoughtful search for treatment and prevention strategies. Efforts have been made in drug repositioning and vaccine development as well as development of monoclonal antibodies. Monoclonal antibodies provide a long-lasting protective immunity against the pathogens, and have been at the forefront line in the therapy of some viral diseases. This study aimed to review the advances in SARS-CoV-2 monoclonal antibodies (mAbs) development. Most of the developed SARS-CoV-2 monoclonal antibodies including; B38, CR3022, 47D11, and H4, have targeted the spike protein of the virus to prevent its interaction with the host cell ACE-2 receptor. However, others such as Tocilizumab prevent the inflammation caused by the cytokine storm.
Keywords
SARS-CoV-2; Spike protein; B cells; T cells; Monoclonal antibodies
Statistics
Article View: 142
PDF Download: 118